Propel Drug-Eluting Sinus Implant Family IBUKI Cohort

NCT07546682 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-23

No results posted yet for this study

Summary

To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.

Conditions

  • Chronic Rhinosinusitis (CRS)

Interventions

OTHER

None, observational standard of care study

None, observational standard of care study

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-05-31
Completion
2027-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546682 on ClinicalTrials.gov